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•	
The World Health Organization encourages 
the promotion and development of 
programmes for the prevention, 
detection, and management of diabetic 
retinopathy (DR). Such programmes must 
identify effective strategies and 
technology so that they can be 
adapted to the situation in each 
part of the world. Programmes 
must also be monitored and 
continuously improved.
The guidelines discussed in 
this article were developed by 
experts brought together during 
workshops hosted by the VISION 
2020 Latin America technical 
subcommittee on DR and 
technical support was provided 
by the Pan-American Asociation 
of Ophthalmology (PAAO). Although these 
guidelines have been developed for Latin 
America, we hope that the principles they 
contain will provide a good starting point 
for the planning of DR services in other 
low- and middle-income countries.
Getting	started	
Before we start planning a DR programme, 
it is helpful to review where we are and 
where we want to be:
•	What is the need for DR services (for 
prevention, diagnosis and treatment) in 
our population?
•	What services and resources are 
required to meet this need?
•	What services and resources are 
already available, and where do these 
fall short of the need?
Doing so will allow us to set goals and 
establish priorities for action.
A programme to manage DR should 
include the following:
•	A good understanding of the current and 
projected prevalence of Dr, to make it 
possible to plan services for prevention, 
screening, and treatment
•	Clinical guidelines with a simple 
classification system, recommended 
examination intervals, and suggestions 
for treatment
•	A way of finding patients with diabetes 
and Dr
•	retinal examination methods that 
take into account available equipment 
and human resources
•	Creation or identification of laser 
treatment centres for timely treatment
•	An education and prevention 
programme that reaches the whole 
population
•	advocacy to secure the support of the 
authorities, educators, general practitioners, 
endocrinologists, and so on
•	long-term sustainability, using cost 
recovery or subsidies (see article on 
page 17 for an example from India).
Estimating	prevalence
The prevalence of DR can be difficult to 
estimate, and few estimates have been 
made in low- and middle-income 
countries. A survey methodology called 
RAAB+DR has been developed to 
estimate the prevalence of DR in a 
population in a quick and affordable way. 
RAAB+DR has been tested in Mexico, 
South Africa, and Saudi Arabia, and the 
results and recommendations will be 
discussed in a future issue of this journal. 
The prevalence of DR in Latin America 
was estimated in 1999. At the initiative of 
the Pan-American Association of 
Ophthalmology, 7,715 patients with 
diabetes from 16 countries were 
assessed. The study found that 40.2% 
showed some degree of DR, that 17% 
needed treatment, and that, most worry-
ingly, 35% had never before been 
examined by an ophthalmologist. A recent 
population-based study in Mexico found 
that the prevalence of diabetes in people 
aged 50 or over was 21%. A total of 39% 
of patients with diabetes had some DR, 
16% had diabetic maculopathy, and 8.6% 
had proliferative DR. Less than half of 
those known to have diabetes had been 
advised to have an annual eye examination.
Developing	clinical	
guidelines
It is important to have a simple, easy-to-
use grading or classification system to 
help standardise appropriate management, 
referral, treatment, and monitoring for 
patients with diabetes. On page 12 of this 
issue, we have published one such system, 
based on the international clinical disease 
severity scale for DR and diabetic 
macular oedema as set out by 
the International Council of 
Ophthalmology (see Useful 
Resources on page 23).
Finding	patients	with	
diabetes	and	DR
Ideally, there should be an 
effective information system 
that identifies people with 
diabetes, calls them for 
screening, and records the 
outcomes of eye examinations 
PLAnnInG
Planning diabetic retinopathy services 
– lessons from Latin America
Fernando	barría	
von-bischhoffshausen
Chair, Prevention of Blindness 
Committee, Pan-American Association 
of Ophthalmology (PAAO).
Francisco	Martinez	Castro
Chair, Subcommittee on Diabetic 
Retinopathy, VISION 2020 
Latin America.
Pedro	Gomez-bastar	
CBM Medical Adviser and Chairman, 
Instituto de la Vision, Universidad de 
Montemorelos, Cabrera Num. 206, 
Colonia del Maestro, Montemorelos, 
NL Mexico, CP 67510.
P
e
d
r
o
 
G
ó
m
e
z
 
B
a
s
t
a
r
Key	learning	points
•	A diabetic retinopathy (DR) 
programme involves more than 
finding patients at risk of DR. There 
must be agreed guidelines on who 
should be examined, referred, or 
treated. An accurate register of 
patients with diabetes is essential, 
and may be difficult to develop.
•	Retinal examination methods should 
be accurate, cost-effective, and cause 
minimal inconvenience for the patient. 
Both retinal photography and retinal 
examination by an ophthalmologist are 
accurate, but photography may be 
more cost-effective in the long-term. 
•	A referral network is essential so that 
any patient with diabetes found to have 
severe retinopathy is guaranteed to 
receive laser treatment if required. 
•	Ophthalmologists should work 
closely with physicians and others to 
ensure that all patients receive 
appropriate eye care, and diabetes 
management, to prevent blindness.
When examining people with diabetes, test their visual 
acuity before you examine their retinas. mEXiCo
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and/or referrals. In Latin America, 
because of its many fragmented health 
care systems, identifying patients with 
diabetes for a national or regional 
screening programme poses a difficult 
challenge. 
Any screening 
programme requires 
clear referral criteria; 
only patients with 
retinopathy meeting a 
pre-defined threshold 
should be referred to 
ophthalmologists. In 
addition, there has to 
be some quality 
control to ensure that 
the screening 
programme is effective. In areas where 
services are available, all patients 
diagnosed as having diabetes should be 
examined. If that is not possible, we 
should consider concentrating on 
high-risk groups, with priority given to 
people with type 1 diabetes, people aged 
50 or over, those with type 2 diabetes of 
more than ten years’ duration, pregnant 
women with gestational diabetes, and 
patients with nephropathy (which can be 
detected by testing for the presence of 
albumen in the urine).
Retinal	examinations
Yearly retinal examinations of all 
diabetes patients are 
necessary because 
the condition is 
asymptomatic in its 
early stages, and 
because early 
treatment reduces 
both the risk of 
blindness and the 
cost of treatment. 
Methods of 
detection include 
the following:
1 retinal examination with a slit 
lamp and hand-held lens following 
pupil dilation. This is the method with 
the greatest specificity (it does not 
tend to wrongly classify someone who 
in fact does not have DR as having 
DR) and sensitivity (it does not tend to 
miss DR in someone who in fact has 
it). However, it is time-consuming and 
hence costly.
2 taking one or two photographs of 
each eye with a non-mydriatic 
camera. This achieves good
sensitivity and specificity. Retinal 
photography with a digital fundus 
camera is rapid and sensitive. 
Although the camera is expensive, 
it may reduce costs as only patients 
with positive findings are referred to 
ophthalmologists. The photographs 
can be taken by technicians, allowing 
ophthalmologists to examine the 
photographs of large numbers of 
patients in a short time.  
3 using a direct or indirect ophthal-
moscope. This has less sensitivity but 
is useful when you do not have a slit 
lamp and lens.
Treatment
DR requires early treatment to slow or 
stop the progression of the disease. 
Improved control of diabetes (page 4) is 
the most important, especially in patients 
with diabetic macular oedema. Patients 
who have established sight-threatening 
retinopathy will require laser treatment. 
Steroids and intravitreal anti-vasculuar 
endothelial growth factor (anti-VEGF) 
therapy are used together with laser 
therapy for macular oedema. Vitrectomy is 
indicated for non-clearing vitreous haemor-
rhage and tractional retinal detachment.
A workable DR programme must have 
the facilities, equipment, consumables, 
medicines, and staff to provide all of 
the above.
 
Education	and	prevention
Education is a priority for the prevention 
of blindness due to diabetic retinopathy.  
There must be clear messages for people 
with diabetes, their families, health 
workers, and the general public, along 
the following lines: 
•	DR is asymptomatic (it has no symptoms), 
and it carries a real risk of blindness.
•	With annual examination of the retina, 
early detection, and prompt laser 
treatment, sight can normally be 
preserved.
•	Strict control of diabetes and blood 
pressure reduces the risk of retinopathy.   
At the primary care level, education 
should focus on lifestyle and 
prevention of diabetes by diet and 
exercise. At the secondary level, 
education should encourage better 
self-care by patients, including improved 
control of blood sugar and blood 
pressure (see article on page 4). 
Education should also promote regular 
eye examinations for all people with 
diabetes. 
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Examining a patient’s retina. mEXiCo
Continues overleaf ➤
‘Retinal examination 
methods should be 
accurate, cost-effective, 
and cause minimal 
inconvenience for 
the patient’
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Effective lobbying or advocacy is 
essential. Advocacy is the act of arguing 
on behalf of a particular cause, such as 
establishing a new DR programme, with 
the aim to influence decision makers to 
support this cause. When planning an eye 
care programme, you should aim to 
develop a solution that is appropriate to 
the local situation and that is directed at 
the population with the greatest needs. 
Aim to ensure the greatest possible 
coverage, quality of care, and sustaina-
bility in the long term.
Political will is needed in order to 
implement eye health policies, and this 
can be generated by effective 
advocacy. Ideally, the eye care 
programme should be developed by a 
working group in which everyone 
involved in the project is represented. 
This group can identify any decision 
makers whose 
support will be 
required and invite 
them to participate. 
The earlier the 
decision makers are 
involved in designing 
the solution, the more 
likely they are to 
support the outcome 
and make helpful 
contributions. This 
turns an obstacle (“How will we get their 
support?”) into an opportunity for 
collaboration. 
Any current inability to meet the 
existing demand for ophthalmological 
services is fertile ground for promoting our 
DR programmes. In Latin America, we 
can deliver clear 
messages to the health 
care authorities or 
legislators along the 
following lines: 
1 Diabetes affects 
7–10% of the 
population over the 
age of 20. Through 
screening, we may find 
retinopathy in as much 
as 30% of patients with diabetes, 
and 5% of patients with diabetes are 
likely to need laser treatment to 
reduce the risk of blindness. 
2 Diabetes will be increasing in the future, 
and it is around twenty times cheaper 
to treat it earlier rather than later. 
3 Eye health plans should be directed 
toward helping the most vulnerable 
people so as to 
achieve equal access to health care.
It is important to describe and publish 
the results of current and past prevention 
of blindness programmes. Publishing in 
scientific journals helps to provide the 
evidence you may need to convince 
decision makers. Persuading the media 
(newspapers, radio and television) to 
then write and talk about this evidence 
creates public pressure that will also 
persuade decision makers to act. 
In Latin America, the epidemic of 
diabetes and DR poses such a great 
challenge to the population’s health 
that we cannot manage alone. Through 
the leadership of the ophthalmology 
societies of Latin America, supranational 
bodies such as the Pan-American 
Association of Ophthalmology (PAAO), 
and other organisations such as the 
Pan-American Health Organization 
(PAHO) and the International Agency for 
the Prevention of Blindness (IAPB), we 
can forge alliances with national govern-
ments. These alliances, when added to 
the initiatives of non-governmental 
organisations, the ophthalmic industry, 
and civil society, can greatly assist with 
the implementation of national plans for 
the detection and control of DR. 
Worldwide, any successful strategy to 
address DR will require close collabo-
ration among everyone concerned: 
ophthalmologists, endocrinologists, 
physicians, mid-level eye care workers, 
outreach workers, pharmacists, public 
health specialists, community leaders, 
politicians, diabetes patients, and the 
general public. 
There is a lot to do, but together we 
can do it!
‘Political will is 
needed in order to 
implement eye health 
policies, and this can 
be generated by 
effective advocacy’
We can do nothing about diabetes or 
diabetic retinopathy (DR) unless we 
know where to find people who have 
diabetes. 
Screening programmes are 
expensive, and countries with limited 
resources should not attempt a 
national screening programme for DR; 
it would be too complex and expensive 
to set up, administer, and manage.
It may be more cost-effective to 
work closely with our colleagues who 
see diabetes patients during the course 
of their work, such as physicians, 
diabetologists, pharmacists, and health 
insurers. We must encourage them to 
look for eye disease in their patients, or 
at the very least to refer their patients 
for regular retinal examination 
(provided that local treatment services 
are available). 
We should also look for diabetes 
patients in our eye clinics, particularly 
those patients with cataract, as 
cataract can be a consequence of 
diabetes. We must check patients’ 
blood sugar (if possible), carefully 
examine their eyes, and refer them for 
follow-up and/or further investigation 
(see the table on page 12). We must 
also ensure that they have access to a 
service to help them manage their 
diabetes. 
However big or small our screening 
programmes, it is important to focus on 
more than the clinical and technical 
aspects (such as camera vs. ophthal-
moscope or technicians vs. 
ophthalmologists). The biggest 
problems are administrative and 
managerial:
•	How do we identify the diabetes 
patients we want to examine? 
•	How do we contact them to come for 
an examination? 
•	What do we do if they don’t turn up? 
•	What do we do if a clear enough view 
of the retina is not possible? 
•	How do we record the findings, and 
how do we share that information? With 
whom do we share it, and when? 
•	Where and how are patients referred? 
•	How many of the people needing 
treatment actually attend and accept 
treatment after referral? 
•	What is the outcome of treatment?
In order for our screening to succeed, it 
is important to address these questions 
as early as possible in any planning 
process.
 
Experiences	in	India
Dr Rajiv Raman and his colleagues in 
India have reported that only 54% of 
the general practitioners or physicians 
they studied were aware of the need 
for annual retinal examinations and 
referral for patients with diabetes. Just 
1.3% used direct ophthalmoscopes to 
detect DR, of which only half dilated 
patients’ pupils before examination. 
The barriers they faced were lack of 
time, lack of ophthalmoscopes and 
lack of training.
According to Dr Raman, diabetes 
patients in India also regularly visit 
their pharmacists. Dr Raman recom-
mends creating awareness among 
general practitioners and pharmacists 
about their role in identifying and 
referring patients at risk of DR. General 
practitioners could also be trained in 
the use of a direct ophthalmoscope 
as part of their continued medical 
education or continued professional 
development.
Finding diabetes patients: thinking beyond the eye clinic
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